logo
Plus   Neg
Share
Email

Total Q1 Profit Rises

Total (TTA.L,TTFNF.PK,TOT) reported that its net income group share for the first-quarter rose to $3.11 billion or $1.16 per share from $2.64 billion or $0.99 per share in the prior year.

But, adjusted net income Group share declined 4% to $2.76 billion from the prior year's reflecting the increase in the net cost of net debt compared to a year ago mainly due to the rise in U.S. dollar interest rates. Adjusted earnings per share decreased by 6% to $1.02, from $1.09 in the prior year.

Revenues from sales for the quarter grew to $45.12 billion from $43.29 billion last year.

The Group is continuing to implement its shareholder return policy. The dividend in euro will be increased by 3.1% in 2019 representing a total increase of 6.5% since 2017 in line with the target increase of 10% over the period 2018-2020.

Total said it will buy back $1.5 billion of shares in 2019 at $60/b as part of its $5 billion share buyback program over the 2018-2020 period, and it will eliminate the scrip dividend option as of June 2019.

The Group maintains its spending discipline in 2019 with a net investment target of $15 billion - $16 billion, cost savings of $4.7 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT